Hydrix Limited · ASX:HYD
Hydrix — Shareholder Meeting (November 2021)
10 slides from Hydrix's shareholder meeting presentation, Nov 24, 2021
Slide 1: Improve a billion lives
hudrix™ Improve a billion lives
Slide 2: Growth through medtech innovation
Sales & For personal use only Distribution Identifying and distributing Growth through medtech innovation high growth medtech products Product Innovation Transforming ideas into commercial products Venture Investment Investing in early-stage high potential medical device companies 2 24 November 2021
Slide 3: Our strategic focus: CVD is the No 1 cause of death globally
For personal use only CVD is the Our strategic focus No 1 Cause of death globally 18million 85% $70B+ Annual global CVD deaths CVD device CVD related caused by heart market by 2027 2 deaths 1 attacks or stroke 1 (1) World Health Organisation June 2021 3 24 November 2021 (2) Global Industry Analysts,
Slide 4: Our objective
For personal use only Product Sales Our objective Three or more CVD devices Investment producing Returns +$50m revenues p.a. Design in 2025 Services 2021 2025 Meeting our objective of becoming a global medtech product company will reshape our revenue mix and earnings. 4 24 November 2021
Slide 5: Realising our objective
For personal use only Realising our objective Product 1 Product 2 Implantable Monitoring Device Cardiovascular Surgery Device Progressing product launches AngelMed Guardian Phyzhon FFR FDA approved implantable continuous Coronary guidewire with integrated in CY22 heart monitor pressure sensor • 45%
Slide 6: Advancing our global medtech strategy
For personal use only Despite COVID causing many disruptions & delays, we achieved significant milestones. Highlights from FY21 and YTD FY22 include: FY21 & YTD FY22 Highlights • Delivered FY21 $7.5m revenues Advancing our global • Achieved FIRST ever sales and implants of the AngelMed Guardian medt
Slide 7: CY22 Outlook
For personal use only CY22 key milestone news flow beginning the first half: CY22 Outlook • Outcome of an Australian Human Ethics Committee review of The Guardian (in progress) Progressing towards • Outcomes of AngelMed Guardian TGA (AUS) and HSA (SNG) regulatory approval process first commercial •
Slide 8: Summary
For personal use only Summary World class team Product sales Board & focused on into the management improving US $70B with a a billion lives CVD market proven track commencing record CY2022 8 24 November 2021
Slide 9: For personal use only
For personal use only
Slide 10: Disclaimer
For personal use only This presentation has been prepared by Hydrix Limited (the “Company” or “Hydrix”). This presentation is being provided to investors for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business activities of